Regeneron’s pivotal trial for an ultra-rare disease fails the primary — but don't count them out at the FDA
Regeneron’s potentially pivotal study for a new drug to treat an ultra-rare and lethal bone disorder failed the primary endpoint — but the R&D team thinks they can still get the ball into the regulatory end zone with the positive data they have on hand.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
